spacer
home > pmps > winter 2017 > working together
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Working Together

If the pharmaceutical supply chain was a living, breathing creature, it would probably be the microscopic water flea. Daphnia pulex was the first crustacean to have its genome sequenced, and results showed that it has 31,000 genes – 25% more than us humans. Just like the genetic complexity of the water flea was a challenge for scientists, the sophisticated pharma supply chain is now changing the way the industry operates.

The rise of emerging markets and the different geographic standards used around the world are additional challenges that manufacturers need to address. As always in the pharma sector, the complex regulatory landscape has a significant impact on companies. This includes widely recognised guidelines such as those from the FDA and their European counterparts, as well as client standards and environmental legislation. All of these factors are contributing to making the supply chain nearly impossible to navigate.

Current Situation

As new markets and technologies emerge in the pharma field, manufacturers are starting to feel the pressure of working with a higher number of suppliers, partners and distributors. They often produce drugs for pharmacies or specific patients, rather than wholesale – this means that the industry is starting to be driven by demand rather than forecast. The medicines themselves are becoming progressively complex and bespoke, meaning that the production of mini batches or personalised medicine is another rising trend.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Darren Halford is Sales Director at obsolete components supplier EU Automation. Previously, he has worked as a recruitment consultant, recommending new employment opportunities to senior construction professionals. Darren oversees all sales and service operations and has been with the company since its inception in May 2009.
spacer
Darren Halford
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement